FISH OIL SUPPLEMENTS MAY IMPROVE MEMORY FUNCTION
Rhode Island Hospital
researchers have completed a study that found regular use of fish oil
supplements (FOS) was associated with a significant reduction in cognitive
decline and brain atrophy in older adults. The study examined the relationship
between FOS use during the Alzheimer's Disease Neuroimaging Initiative (ADNI)
and indicators of cognitive decline. The findings are published online in
advance of print in the journal Alzheimer's
& Dementia
At least one person is
diagnosed every minute with Alzheimer's disease (AD) and despite best efforts,
we have not yet found a cure for this pervasive and debilitating disease,"
said principal investigator Lori Daiello, PharmD, of the Alzheimer's Disease and
Memory Disorders Center at Rhode Island Hospital. "The field is currently
engaged in numerous studies to find better treatments for people suffering with
AD; however, researching ways to prevent AD or slow cognitive decline in normal
aging is of utmost importance."
In this retrospective
study, older adults involved in the ADNI study were assessed with
neuropsychological tests and brain magnetic resonance imaging (MRI) every six
months. The group included 229 older adults who were cognitively normal; 397 who
were diagnosed with mild cognitive impairment; and 193 with AD.
The study found that
fish oil supplement use during the study was associated with significantly
lower rates of cognitive decline as measured by the Alzheimer's Disease
Assessment Scale (ADAS-cog), and the Mini Mental State Exam (MMSE), but this
benefit was observed only for the group of participants without dementia at the
time of enrollment.
"Additionally,
serial brain imaging conducted during this study showed that the participants
with normal cognition who reported taking fish oil supplements demonstrated
less brain shrinkage in key neurological areas, compared to those who did not
use the supplements," Daiello said. "Also, the positive findings on
cognitive testing and brain MRI were only observed in persons who did not carry
the best-studied genetic risk factor for AD, APOE-4. More research is needed,
but these findings are promising and highlight the need for future studies to
expand the current knowledge of the effects of FOS use on cognitive aging and
AD."
It is estimated that
more than 5 million people in the U.S. have Alzheimer's disease. It is the most
common form of dementia and is the sixth leading cause of death in the U.S.
Comments
Post a Comment